CD274 and neoplasm: Although the initial reports indicated that PD-L1 expressed in both tumor cells and non-tumor host cells contributes to PD-L1/PD-1 checkpoint blockade therapies [2,3], the host expression of PD-L1 has been shown to contribute to the efficacy of PD-L1 pathway blockade-mediated tumor regression.